Albireo

News

Acquisitive Ipsen builds again with $952m Albireo buy

French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.

Views & Analysis

Q-and-A-Albireo’s-Ron-Cooper-on-bile-acid-modulation

Q&A: Albireo’s Ron Cooper on bile acid modulation

While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks